Immunine (Human Coagulation Factor Ix)

Human Coagulation Factor IX, the active ingredient in Immunine, is a coagulation factor replacement therapy presented as a sterile intravenous solution for intravenous use. It is used to treat patients with Hemophilia B or other Factor IX deficiencies by restoring normal clotting function. GNH USA supplies Immunine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Immunine is a recombinant coagulation factor that replaces deficient Factor IX in the intrinsic pathway of blood clotting. It is indicated for: - Hemophilia B: provides factor IX replacement to prevent and control bleeding episodes. - Factor IX deficiency: restores clotting ability in congenital or acquired deficiency states. - Peri‑operative management in Hemophilia B: ensures adequate hemostasis during surgical or invasive procedures.

Immunine may be associated with infusion‑related and immune‑mediated reactions.

Common Side Effects: - Infusion site erythema or swelling - Fever or chills during administration - Headache or mild dizziness - Nausea or abdominal discomfort

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Development of neutralizing inhibitors (antibodies) to Factor IX - Thrombotic events such as deep‑vein thrombosis or pulmonary embolism - Transmission of viral contaminants (theoretical risk) - Renal impairment or hemolysis in susceptible patients

Before initiating Immunine therapy, clinicians should consider several safety